- Top Workplaces
- Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Alnylam has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and Leqvio® (inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development.
Vision
Harnessing a revolution in biology for human health.
Mission
Build a top-tier, global, independent biopharmaceutical company founded on RNAi.
Values
- Fiercely Innovative
- Transformational, world leading science and flawless execution are at the heart of who we are.
This means that we:
- Aspire to drive new discoveries from concept to cure
- Demand innovation from across the company for the benefit of patients globally
- Strive for a workplace environment that crackles with creativity and collaboration
To be Fiercely Innovative, we need to:
- Have a deep understanding of the critical issues we’re trying to solve
- Create an environment that provides headspace to promote innovation and strategic thinking
- Have the courage to take appropriate risks to meet the needs of our patients
- Learn from our successes and failures
Recent Awards
Company Snapshots
